Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule.

Front Pharmacol · 2017 · PMC5545583 · PMID 28824438

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Overall, the conclusion of those studies is the same, with a highly significant reduction of moderate-to-severe toxic effects, namely diarrhea, fatigue, mucositis, thrombocytopenia, and hypertension in the alternative schedule (Bracarda et al., 2015 ; Gore et al., 2015 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.